Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

19.84

Margin Of Safety %

Put/Call OI Ratio

0.69

EPS Next Q Diff

0.86

EPS Last/This Y

-4.35

EPS This/Next Y

4.91

Price

21.55

Target Price

20.43

Analyst Recom

2.77

Performance Q

19.06

Relative Volume

0.6

Beta

0.48

Ticker: SRPT




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-17SRPT17.520.670.49229871
2025-11-18SRPT17.420.670.55231179
2025-11-19SRPT16.390.661.53232053
2025-11-20SRPT16.490.660.49234227
2025-11-21SRPT17.680.660.42234300
2025-11-24SRPT18.920.720.19170180
2025-11-25SRPT19.360.700.42172479
2025-11-26SRPT20.930.690.34174706
2025-12-01SRPT19.760.690.44173374
2025-12-02SRPT20.480.680.68175012
2025-12-03SRPT21.790.680.34176168
2025-12-04SRPT22.840.690.61176619
2025-12-05SRPT22.270.700.49176875
2025-12-08SRPT21.870.700.84170653
2025-12-09SRPT22.170.701.00172425
2025-12-10SRPT22.180.700.58172711
2025-12-11SRPT21.750.701.53172839
2025-12-12SRPT21.540.711.62174387
2025-12-15SRPT21.540.691.73170982
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-17SRPT17.52-151.6363.3-2.24
2025-11-18SRPT17.41-145.7370.6-2.24
2025-11-19SRPT16.39-145.7364.3-2.24
2025-11-20SRPT16.46-143.4371.8-2.24
2025-11-21SRPT17.68-143.4379.6-2.07
2025-11-24SRPT18.92-147.9379.3-2.18
2025-11-25SRPT19.35-147.9374.0-2.18
2025-11-26SRPT20.97-147.9381.1-2.18
2025-12-01SRPT19.72-140.9362.2-2.01
2025-12-02SRPT20.47-140.9375.8-2.01
2025-12-03SRPT21.84-140.9379.2-2.01
2025-12-04SRPT22.83-140.9376.7-2.01
2025-12-05SRPT22.26-140.9368.3-2.01
2025-12-08SRPT21.86-140.9- -2.01
2025-12-09SRPT22.17-140.9373.0-2.01
2025-12-10SRPT22.18-140.9371.3-2.01
2025-12-11SRPT21.74-137.3369.0-2.01
2025-12-12SRPT21.54-137.3370.1-2.01
2025-12-15SRPT21.55-137.3371.4-2.01
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-17SRPT0.008.6117.46
2025-11-18SRPT0.008.6117.46
2025-11-19SRPT0.008.6117.46
2025-11-20SRPT0.008.6117.46
2025-11-21SRPT0.008.6117.46
2025-11-24SRPT0.005.2417.53
2025-11-25SRPT0.005.2417.53
2025-11-26SRPT0.005.2418.23
2025-12-01SRPT0.005.1618.23
2025-12-02SRPT0.005.1618.23
2025-12-03SRPT0.005.1618.23
2025-12-04SRPT0.005.1618.23
2025-12-05SRPT0.005.1618.23
2025-12-08SRPT0.005.1518.23
2025-12-09SRPT0.005.1518.23
2025-12-10SRPT0.005.1519.81
2025-12-11SRPT0.005.1519.81
2025-12-12SRPT0.005.1519.81
2025-12-15SRPT0.005.3219.84
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

[stock_market_widget type="chart" template="candlestick" assets="SRPT" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS

-0.13

Avg. EPS Est. Current Quarter

-0.71

Avg. EPS Est. Next Quarter

0.73

Insider Transactions

Institutional Transactions

5.32

Beta

0.48

Average Sales Estimate Current Quarter

379

Average Sales Estimate Next Quarter

375

Fair Value

Quality Score

43

Growth Score

39

Sentiment Score

22

Actual DrawDown %

88.2

Max Drawdown 5-Year %

-93.3

Target Price

20.43

P/E

Forward P/E

11.74

PEG

3.63

P/S

0.94

P/B

1.71

P/Free Cash Flow

EPS

-2.89

Average EPS Est. Cur. Y​

-2.01

EPS Next Y. (Est.)

2.9

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-11.25

Relative Volume

0.6

Return on Equity vs Sector %

-47.6

Return on Equity vs Industry %

-32.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.05

EBIT Estimation

371.4
[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”SRPT” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”SRPT” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”SRPT” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”SRPT” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”SRPT” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”SRPT” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”SRPT” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
Sarepta Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 1372
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
stock quote shares SRPT – Sarepta Therapeutics, Inc. Stock Price stock today
news today SRPT – Sarepta Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SRPT – Sarepta Therapeutics, Inc. yahoo finance google finance
stock history SRPT – Sarepta Therapeutics, Inc. invest stock market
stock prices SRPT premarket after hours
ticker SRPT fair value insiders trading